MK8527-007 Study

MK8527-007 Study: Investigating Monthly Oral HIV Prevention

Rationale

With ongoing efforts to improve HIV prevention methods, there is a need for innovative, long-acting solutions that simplify adherence and offer greater flexibility compared to daily oral regimens. The MK8527-007 study evaluates the safety, tolerability, and pharmacokinetics of a once-monthly oral HIV prevention medication, MK-8527, in participants at low risk for HIV-1 infection. This study aims to provide critical insights into the potential of MK-8527 as a convenient and effective option for HIV prevention.

Primary Objectives

1. Safety and Tolerability: To evaluate the safety and tolerability of MK-8527 at three different doses (3 mg, 6 mg, and 12 mg) administered once monthly (QM) during treatment and through the final follow-up visit.
2. Adverse Events: To monitor adverse events and any events leading to the discontinuation of the study intervention.

Study Population

The study targets adults aged 18-65 years who are at low risk of HIV-1 infection.

Sponsors

The study is sponsored by Merck Sharp & Dohme LLC (MSD).

Investigators

Principal Investigator: Dr Nicole Poovan

Latest Update

April 2024

For more details about MK8527-007 study please email rhicomms@wrhi.ac.za

Click here for further details regarding the MK8527-007 study.